It’s been a wild Monday for Amarin (AMRN). The biopharma company’s stock price is soaring on the readout of a large clinical trial showing its proprietary, prescription formulation of fish oil cut the risk of bad cardiovascular events like heart attacks and stroke in patients by an astounding 25 percent.

With these new study results, Amarin and its omega-3 capsules — sold under the brand name Vascepa — are poised to make heart-medicine history. What was a niche commercial product may soon become a gold standard, add-on therapy to statins prescribed to millions of Americans. Billions of dollars in sales are potentially up for grabs for Amarin.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Omega-3s increase vascular prostacyclin, which greatly inhibits platelet aggregation. A colleague of mine, Dr. Jim Aiken, found he could inhibit heart attacks in dogs when he almost totally occluded the coronary artery in dogs as long as they were getting an infusion of prostacyclin. I suspect that studies of high dose fish oil, whether prescription or not, will continue to show great promise in cardiovascular disease.

    • Excellent information. Every fish oil I know except for Vascepa, prescription or not, and especially non-prescription, has DHA, which increases LDL-C, known to have a negative effect on the morphology and synthesis of prostacyclin, counter to that of HDL-C. That’s why no clinical study of over-the-counter fish oil usage has proven a reduction in meaningful MACE statistics.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy